| Budget Amount *help |
¥14,300,000 (Direct Cost: ¥11,000,000、Indirect Cost: ¥3,300,000)
Fiscal Year 2015: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2014: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2013: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
|
|---|
| Outline of Final Research Achievements |
Thirty seven patients with metastatic or recurrent sarcomas were enrolled in this study. Peripheral blood mononuclear cells obtained from the patients were suspended in media containing IL-4 and GM-CSF. These cells were treated with tumor lysate, TNF-α, and OK-432. One treatment course comprised weekly DC injection for 6 times. Toxicity, clinical response (tumor volume, serum IFN-γ, and serum IL-12), and oncological outcomes were observed. DC therapy were performed in 37 patients. No severe adverse event and death associated with the DC injections were observed in the study patients. Increased serum IFN-γ and IL-12 were observed 1 month after DC injection. 6 cases had stable disease, and 1 case showed partial response 3 months after DC therapy. Of the 37 patients, 13 patients were alive and 1 patient was progression free at the time of the final follow-up. Overall survival rates and progression free survival rates of the patients at 3 years were 42.3% and 2.9%, respectively.
|
